Celebrini scores first career OT goal as Sharks top Red Wings 5-4

SAN JOSE, Calif. (AP) — Rookie sensation Macklin Celebrini scored 46 seconds into overtime, and the San Jose Sharks beat the slumping Detroit Red Wings 5-4 on Monday night.

William Ecklund had two goals, and Luke Kunin and Tyler Toffoli also scored for San Jose. who have won two straight and are 3-1-2 in their last six games. Mackenzie Blackwood finished with 16 saves.

Dylan Larkin had a goal and had an assist, and Alex DeBrincat, Marco Kasper and Michael Rasmussen also scored for Detroit, which has lost five of six. Cam Talbot stopped 29 shots.

Detroit trailed 4-3 with 2:06 left in regulation when DeBrincat tied it on a power-lay goal.

Celebrini, the 2024 No. 1 overall draft pick, then won it in the extra period with his fourth goal of the season and first career overtime score.

Red Wings: Detroit led 3-2 midway through the second period when Michael Rasmussen was credited with the score on an own goal, but they were unable to close the game.

Sharks: The rebuilding Sharks are 6-5 since losing nine straight to start the season. They trailed most of the game but played inspired hockey, especially late, as they rallied for the win.

DeBrincat sent the game to overtime on a power-play goal that came 1:40 after Ty Dellandrea was assessed a 2-minute penalty for tripping Erik Gustafsson.

The Sharks outshot the Red Wings 34-20.

Red Wingst host the New York Islanders on Thursday, and Sharks visit Dallas on Wednesday.

AP NHL: https://apnews.com/hub/nhl

San Jose Sharks center Will Smith (2) reaches for the puck against Detroit Red Wings defenseman Ben Chiarot (8) and goaltender Cam Talbot (39) during the third period of an NHL hockey game in San Jose, Calif., Monday, Nov. 18, 2024. (AP Photo/Jeff Chiu)

San Jose Sharks left wing William Eklund (72) skates toward the puck in front of Detroit Red Wings right wing Christian Fischer during the first period of an NHL hockey game in San Jose, Calif., Monday, Nov. 18, 2024. (AP Photo/Jeff Chiu)

Detroit Red Wings center Andrew Copp, top, falls to the ice over San Jose Sharks center Tyler Toffoli during the second period of an NHL hockey game in San Jose, Calif., Monday, Nov. 18, 2024. (AP Photo/Jeff Chiu)

San Jose Sharks center Macklin Celebrini (71) skates with the puck against the Detroit Red Wings during the first period of an NHL hockey game in San Jose, Calif., Monday, Nov. 18, 2024. (AP Photo/Jeff Chiu)

Detroit Red Wings right wing Alex DeBrincat skates with the puck against the San Jose Sharks during the first period of an NHL hockey game in San Jose, Calif., Monday, Nov. 18, 2024. (AP Photo/Jeff Chiu)

San Jose Sharks head coach Ryan Warsofsky, top middle, reacts behind players on the bench during the third period of an NHL hockey game against the Detroit Red Wings in San Jose, Calif., Monday, Nov. 18, 2024. (AP Photo/Jeff Chiu)

San Jose Sharks left wing William Eklund, middle, is congratulated by teammates after scoring against the Detroit Red Wings during the second period of an NHL hockey game in San Jose, Calif., Monday, Nov. 18, 2024. (AP Photo/Jeff Chiu)

San Jose Sharks center Macklin Celebrini, middle, is congratulated by teammates after scoring the winning goal during overtime of an NHL hockey game against the Detroit Red Wings in San Jose, Calif., Monday, Nov. 18, 2024. (AP Photo/Jeff Chiu)

NIJMEGEN, The Netherlands--(BUSINESS WIRE)--Nov 19, 2024--

Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the appointment of Louis Denis, M.D. as Chief Medical Officer. Dr. Denis brings more than 30 years of clinical development leadership and oncology expertise to Byondis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241118495587/en/

“We are excited that Louis has joined the Byondis team. Building on our successful proprietary drug discovery, research and development and in-house CMC capabilities, his proven track record and expertise in cancer drug development will be invaluable to rapidly advance our pipeline through the clinic and ultimately reach patients,” said Byondis’ Founder and CEO Jacques Lemmens, Ph.D.

"Byondis is uniquely positioned to make meaningful contributions to cancer care based on its deep scientific knowledge, strong research capabilities and broad pipeline of new antibody-drug conjugates and antibody-based therapeutics,” said Dr. Denis. “I look forward to working together to advance and deliver the next generation of targeted cancer treatments for patients.”

Prior to joining Byondis, Dr. Denis was the Chief Medical Officer at Verastem Oncology and at Asana BioSciences since 2015. Previously, Dr. Denis held various leadership roles in Oncology clinical development and medical affairs at Boehringer Ingelheim and Pfizer. Dr. Denis received his M.D. from the Vrije Universiteit Brussel, Belgium, and did his post-doctoral fellowships in Internal Medicine/Medical Oncology at Middelheim Hospital, Antwerp; the Rotterdam Cancer Institute, The Netherlands; and the Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas.

About Byondis

Driven to improve patients’ lives, Byondis is an independent clinical stage biopharmaceutical research and development company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) focusing on antibody-drug conjugates and antibody-based therapeutics.

Byondis’ broad development portfolio comprises preclinical and early-stage clinical programs. The product candidates combine Byondis’ expertise in linker-drug (LD) technology, antibody-drug conjugation, targeted cytotoxic therapy, immunology, and monoclonal antibody (mAb) development. Byondis’ expertise covers all preclinical R&D from early lead finding to production of clinical batches of the selected product candidates, which are all done in-house.

The company has a dedicated team of more than 300 staff working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. For more information visit www.byondis.com.

Louis Denis, M.D., Chief Medical Officer, Byondis (Photo: Business Wire)